Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1353-1364

  Obritsch, Marilee D ^a   Fish, Douglas N ^b   MacLaren, Robert ^b   Jung, Rose ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antibiotic resistance; Multidrug resistant; Nosocomial infections; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CREATININE; GENTAMICIN; IMIPENEM; ISEPAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULPERAZON; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATE; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DRUG EFFICACY; ECONOMIC ASPECT; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KIDNEY FAILURE; KIDNEY FUNCTION; LENGTH OF STAY; MEDLINE; MULTIDRUG RESISTANCE; MUSCLE WEAKNESS; NOMENCLATURE; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SIDE EFFECT; STANDARDIZATION;

ANTI-BACTERIAL AGENTS; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 26044458858     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1353     Document Type: Review

References (63)

1. Brewer SC, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-29.
2. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128-33.
3. Arts RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yakaskas JR. The effects of panresistant bacteria in cystic fibrosis on lung transplant outcome. Am J Respir Crit Care Med 1997;155: 1699-704.
4. Hsueh PR, Teng LJ, Yang PC, Chen UC, Ho SW, Luh KT. Persistence of a multi-drug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 1998;36:1347-51.
5. Verweij PE, Bijl D, Melchere WJ, et al. Pseudo-outbreak of multiresistant Pseudomonas aeruginosa in hematology unit. Infect Control Hosp Epidemiol 1997;18:128-31.
6. Richard P, LeFloch R, Chamoux C, Pannier M, Espaze E, Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis 1994;170:377-83.
7. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998;39:53-62.
8. Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002;8:220-1.
9. Arruda EAG, Marinho IS, Boulos M, et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 1999;20:620-3.
10. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131-8.
11. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-51.
12. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
13. Ibraham EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
14. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8.
15. Sofianou D, Tsakris A, Skoura L, Douboyas J. Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. J Antimicrob Chemother 1997;40:740-2.
16. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32:S146-55.
17. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004;48: 4606-10.
18. Furuta I, Yamazumi T, Kitahashi T, Iimori M, Satou K, Maeno T. Antimicrobial susceptibility pattern and epidemiological investigation of the clinical isolates of Pseudomonas aeruginosa in 1999 and 2000 [in Japanese]. Rinsho Biseibutsu Jinsoku Shindan Kenkyukai Shi 2001;12:23-30.
19. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonos aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002;34:1047-54.
20. D'Agata EMC. Rapidly rising prevalence of nosocomial multidrug-resistant, gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004;25:842-6.
21. Jung R, Fish DN, Obritsch MD, et al. Prevalence of multidrug resistant Pseudomonos aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 2004;57:105-11.
22. Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ. Emergence of highly antibiotic-resistance Pseudomonas oeruginoso in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 1999;7:83-7.
23. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670-7.
24. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. 2004;57:112-18.
25. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonos aeurginosa. Arch Intern Med 1999;159:1127-32.
26. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
27. Studemeister AE, Quinn JP. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob Agents Chemother 1988;32:1267-8.
28. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998;4:257-61.
29. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:479-87.
30. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-7.
31. 2+ environments. J Bacteriol 1997;179:7040-5.
32. Ziha-Zarifi I, Lianes C, Kohler T, Pechere J, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonos oeruginoso overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999;43:287-91.
33. Pumbwe L, Piddock LJV. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:2861-4.
34. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001;3:255-64.
35. Wolter DJ, Smith-Moland E, Goering RV, Hanson DN, Lister PD. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn Microbiol Infect Dis 2004;50:43-50.
36. Domenig C, Traunmuller F, Kozek S, et al. Continuous β-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation 2001;71:744-5.
37. Baines RD Jr, Rifkind D. Intravenous administration of sodium colistimethate.JAMA 1964;190:278-81.
38. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90.
39. Jones RN, Anderegg TR, Swenson JM, and the Quality Control Working Group. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 2005;43:925-7.
40. Koch-Weser J, Sidel VW, Federraan EG, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Int Med 1970;72:857-68.
41. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
42. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003;7: R78-83.
43. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62.
44. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa [online exclusive article]. Clin Infect Dis 2003;37:e154-60. Available from www.journals.uchicago.edu/CID/ journal/issues/v37n11/31371/31371.html.
45. Tascini C, Gemignani G, Ferranti S, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004;16:282-7.
46. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-30.
47. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
48. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-9.
49. Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998;42:953-5.
50. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40:677-83.
51. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003;21:8-12.
52. Drago L, DeVecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy 2004;50:202-10.
53. Oie S, Sawa A, Kamiya A, Mizuno H. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1999;44:689-91.
54. Oie S, Uematsu T, Sawa A, et al. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003;52:911-14.
55. Roussel-Delvallez M, Wallet F, Delpierre F, Courcol RJ. In vitro bactericidal effect of a β-lactam + aminoglycoside combination against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother 1996;8:365-8.
56. Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, Plachouras D, Tsaganos T, Giamarellou H. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2005;51:113-17.
57. Erdem I, Kucukercan M, Ceran N. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 2003;49:294-7.
58. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1997;29:81-6.
59. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003;15:235-8.
60. Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of β-lactam resistance. J Clin Microbiol 2001;39:2072-8.
61. Fraser TG, Reiner S, Malczynski M, Yarnold PR, Warren J, Noskin GA. Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangio-pancreatography: failure of routine endoscope culture to prevent an outbreak. Infect Control Hosp Epidemiol 2004;25:856-9.
62. Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985;121:182-205.
63. Bryce EA, Smith JA. Focused microbiological surveillance and gram-negative β-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995;16:331-4.